Search

everythinglearnresearchcommunity

for

Search:↓

Women with PCOS have similar bone density to healthy women, but those who are obese have higher bone density at some body sites.

New hair loss treatments may include topical medications, injections, and improved transplant methods.

Nandrolone might increase muscle mass with fewer side effects than testosterone but could cause erectile dysfunction and needs more research.

A small number of premenopausal female blood donors had high prolactin levels, often due to stress, and retesting is recommended to prevent misdiagnosis.

Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.

We need better ways to test and understand SARMs to make safer and more effective treatments.

The conclusion is that standardizing testosterone measurement methods is essential for better diagnosis accuracy in women.

Hair follicles help substances penetrate the skin faster and more effectively.

Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.

Effective, well-tolerated, and affordable treatments are needed for recurrent ischemic priapism.

The IRS-2 Asp/Asp genotype may increase the risk of PCOS in Chinese women, especially if they are not obese.

The conclusion is that metformin is a first-line treatment for PCOS, particularly for restoring ovulation and increasing pregnancy rates, with other treatments depending on specific symptoms.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.

Certain gene variants in estrogen receptors are linked to polycystic ovary syndrome, mainly affecting metabolism, in Tunisian women.

The conclusion is that managing cholesterol is important for women, especially during pregnancy, breastfeeding, and with PCOS, and involves regular screening and careful treatment choices.

The document concludes that managing PCOS involves treating symptoms, regulating periods, and reducing health risks, with specific medications for fertility and metabolic issues.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

The document concludes that managing female hyperandrogenism requires a combination of identifying the cause, lifestyle changes, medication, and cosmetic treatments.

Hair loss drugs like finasteride may cause lasting sexual and mood side effects, and more research is needed to understand these risks.

Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

A woman was the first known case to have both polycystic ovary syndrome and autoimmune polyglandular syndrome type 2, suggesting a need to check for both conditions in similar patients.

Melatonin receptors in hair follicles help regulate hair growth and could treat hair loss.

Testosterone therapy can help women with androgen deficiency by improving energy, sex drive, and bone health with few side effects.

Different levels of anti-Müllerian hormone can help diagnose polycystic ovary syndrome in women of different ages.

Finasteride treatment changes urine metabolomics and steroid signatures, potentially monitoring effectiveness but may cause sexual side effects.

Finasteride affects SRD5A2 gene pattern, possibly causing lasting side effects.

Chesapeake Bay retrievers' hair loss is likely a breed-specific, hereditary condition linked to abnormal steroid levels and distinct skin changes.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Using rodents for research shows that health problems in the womb can cause diseases later in life.